삼성서울병원

Ko En
의료진 검색
찾으실 의료진명을 입력하여 검색해주세요.

혈액종양내과 김승태 교수

진료분야
위암, 대장암, 췌담도암, 희귀부인암
진료일정 04 月
날짜
수
01
목
02
금
03
토
04
일
05
월
06
화
07
수
08
목
09
금
10
토
11
일
12
월
13
화
14
수
15
목
16
금
17
토
18
일
19
월
20
화
21
수
22
목
23
금
24
토
25
일
26
월
27
화
28
수
29
목
30
오전
오후
진료일정 05 月
날짜
금
01
토
02
일
03
월
04
화
05
수
06
목
07
금
08
토
09
일
10
월
11
화
12
수
13
목
14
금
15
토
16
일
17
월
18
화
19
수
20
목
21
금
22
토
23
일
24
월
25
화
26
수
27
목
28
금
29
토
30
일
31
오전
오후
본원외래 본원클리닉 본원육아상담 암병원외래 암병원클리닉 암병원육아상담
" 개인 맞춤 치료를 통해
암 환자들의 새로운 희망이 되다 "

김승태 교수는 위암과 대장암 분야의 항암 치료를 주 전문으로 하며, 암세포의 표적인자를 찾아내고 이에 맞는 개인맞춤 치료제를 찾아내기 위한 연구를 주로 하고 있습니다. 5년 뒤 환자들이 세계에서 가장 앞선 위암, 대장암 치료를 받을 수 있도록 더욱 노력하겠다는 김승태 교수는 오늘도 환자에게 도움이 될 수 있는 연구에 박차를 가하고 있습니다.

SMC 블로그 바로가기

학력

학력
2011.02 성균관대학교 대학원 의학과 박사 졸업
2005.02 성균관대학교 대학원 의학과 석사 졸업
2001.02 동국대학교 의과대학 졸업

경력

경력
2017.03 ~현재 삼성서울병원 혈액종양내과 부교수
2013.11 ~ 2017.02 삼성서울병원 혈액종양내과 진료조교수
2013.03 ~ 2013.10 고려대학교 의과대학 내과 조교수
2010.03 ~ 2013.02 고려대학교 안암병원 종양내과 임상조교수
2009.05 ~ 2010.02 삼성서울병원 혈액종양내과 임상강사
2007.05 ~ 2009.04 보건산업진흥원 연구원
2002.03 ~ 2006.02 삼성서울병원 내과 레지던트 과정 수료
2001.03 ~ 2002.02 삼성서울병원 인턴 과정 수료
논문
  • CLIN CANCER RES 2019 10.1158/1078-0432.CCR-19-1324 Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel Willis1, J; Lefterova, MI; Artyomenko, A; Kasi, PM; Nakamura, Y; Mody, K; Catenacci, DVT; Fakih, M; Barbacioru, C; Zhao, J; Sikora, M; Fairclough, SR; Lee, H; Kim, KM; Kim, ST; Kim, J; Gavino, D; Benavides, M; Peled, N; Nguyen, T; Cusnir, M; Eskander, RN; Azzi, G; Yoshino, T; Banks, KC; Raymond, VM; Lanman, RB; Chudova, DI; Talasaz, A; Kopetz, S; Lee, J; Odegaard, JI
    View PubMed
  • CLIN CANCER RES 2019 10.1158/1078-0432.CCR-19-1704 Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma Maron1, SB; Chase, LM; Lomnicki, S; Kochanny, S; Moore, KL; Joshi, SS; Landron, S; Johnson, J; Kiedrowski, LA; Nagy, RJ; Lanman, RB; Kim, ST; Lee, J; Catenacci, DVT
    View PubMed
  • TRANSL ONCOL 2019 10.1016/j.tranon.2019.07.017 Cancer Panel Assay for Precision Oncology Clinic: Results from a 1-Year Study Kwon1, D; Kim, B; Shin, HC; Kim, EJ; Ha, SY; Jang, KT; Kim, ST; Lee, J; Kang, WK; Park, JO; Kim, KM
    View PubMed
  • INT J CANCER 2019 10.1002/ijc.32228 Bridging genomics and phenomics of gastric carcinoma Cho1, J; Ahn, S; Son, DS; Kim, NKD; Lee, KW; Kim, S; Lee, J; Park, SH; Park, JO; Kang, WK; An, JY; Choi, MG; Lee, JH; Sohn, TS; Bae, JM; Kim, S; Kim, KM
    View PubMed
  • Front Oncol 2019 10.3389/fonc.2019.01327 Systematic Evaluation of Gastric Tumor Cell Index and Two-Drug Combination Therapy via 3-Dimensional High-Throughput Drug Screening Lim1, SH; Sa, JK; Lee, DW; Kim, J; Kim, ST; Park, SH; Ku, B; Park, JO; Park, YS; Lim, H; Kang, WK; Nam, DH; Lee, J
    View PubMed
  • ONCOLOGIST 2019 10.1634/theoncologist.2019-0121 FGFR2-Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape Klempner1, SJ; Madison, R; Pujara, V; Ross, JS; Miller, VA; Ali, SM; Schrock, AB; Kim, ST; Maron, SB; Dayyani, F; Catenacci, DVT; Lee, J; Chao, J
    View PubMed
  • CANCER DISCOV 2019 10.1158/2159-8290.CD-19-0442 Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial Lee1, J; Kim, ST; Kim, K; Lee, H; Kozarewa, I; Mortimer, PGS; Odegaard, JI; Harrington, EA; Lee, J; Lee, T; Oh, SY; Kang, JH; Kim, JH; Kim, Y; Ji, JH; Kim, YS; Lee, KE; Kim, J; Sohn, TS; An, JY; Choi, MG; Lee, JH; Bae, JM; Kim, S; Kim, JJ; Min, YW; Min, BH; Kim, NKD; Luke, S; Kim, YH; Hong, JY; Park, SH; Park, JO; Park, YS; Lim, HY; Talasaz, A; Hollingsworth, SJ; Kim, KM; Kang, WK
    View PubMed
  • J Cancer 2019 10.7150/jca.37610 Capecitabine plus Oxaliplatin as a Second-Line Therapy for Advanced Biliary Tract Cancers: A Multicenter, Open-Label, Phase II Trial Kim1, ST; Oh, SY; Lee, J; Kang, JH; Lee, HW; Lee, MA; Sohn, BS; Hong, JH; Park, YS; Park, JO; Lim, HY
    View PubMed
  • SCI REP-UK 2019 10.1038/s41598-019-51981-5 Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients Bray1, SM; Lee, J; Kim, ST; Hur, JY; Ebert, PJ; Calley, JN; Wulur, IH; Gopalappa, T; Wong, SS; Qian, HR; Ting, JC; Liu, JG; Willard, MD; Novosiadly, RD; Park, YS; Park, JO; Lim, HY; Kang, WK; Aggarwal, A; Kim, HC; Reinhard, C
    View PubMed
  • ANTICANCER RES 2019 10.21873/anticanres.13785 Clinical Outcomes and the Role of Adjuvant Concurrent Chemoradiation Therapy in D2-resected LN-positive Young Patients (<= 45 Years) With Gastric Cancer Yu1, JI; Lim, DH; Lee, J; Kang, WK; Park, SH; Park, JO; Lim, HY; Kim, ST; Kim, S; Sohn, TS; Lee, JH; An, JY; Choi, MG; Bae, JM; Kim, HS; Ahn, S
    View PubMed
  • J IMMUNOTHER 2019 10.1097/CJI.0000000000000283 LAG3 in Solid Tumors as a Potential Novel Immunotherapy Target Lee1, SJ; Byeon, SJ; Lee, J; Park, SH; Park, JO; Park, YS; Kang, WK; Lim, HY; Kim, KM; Kim, ST
    View PubMed
  • Transl Cancer Res 2019 10.21037/tcr.2019.09.27 Detection of circulating tumor cells (CTCs) in cerebrospinal fluid of a patient with HER2-overexpressing gastric cancer and single cell analysis of intra-patient heterogeneity of CTCs Cho1, JH; Kim, SY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST
    View PubMed
  • ONCOLOGIST 2019 10.1634/theoncologist.2019-0221 A Randomized Controlled Trial of Epidermal Growth Factor Ointment for Treating Epidermal Growth Factor Receptor Inhibitor-Induced Skin Toxicities Kim1, YS; Ji, JH; Oh, SY; Lee, S; Huh, SJ; Lee, JH; Song, KH; Son, CH; Roh, MS; Lee, GW; Lee, J; Kim, ST; Kim, CK; Jang, JS; Hwang, IG; Ahn, HK; Park, LC; Oh, SY; Kim, SG; Lee, SC; Lim, DH; Lee, SI; Kang, JH
    View PubMed
  • PATHOL RES PRACT 2019 10.1016/j.prp.2019.152434 CCNE1 amplification is associated with liver metastasis in gastric carcinoma Kim1, B; Shin, HC; Heo, YJ; Ha, SY; Jang, KT; Kim, ST; Kang, WK; Lee, J; Kim, KM
    View PubMed
  • THER ADV MED ONCOL 2019 10.1177/1758835919871126 Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group Yoo1, C; Im, HS; Kim, KP; Oh, DY; Lee, KH; Chon, HJ; Kim, JH; Kang, M; Kim, I; Lee, GJ; Oh, SY; Choi, Y; Choi, HJ; Kim, ST; Park, JO; Ryoo, BY
    View PubMed
  • BMC CANCER 2019 10.1186/s12885-019-6030-5 Comprehensive molecular and clinical characterization of Asian melanoma patients treated with anti-PD-1 antibody Lee1, J; Lee, SJ; Kim, K; Kim, ST; Lee, J
    View PubMed
  • J MOL DIAGN 2019 10.1016/j.jmoldx.2019.02.007 Tumor Heterogeneity Index to Detect Human Epidermal Growth Factor Receptor 2 Amplification by Next-Generation Sequencing A Direct Comparison Study with Immunohistochemistry Choi1, S; Chu, J; Kim, B; Ha, SY; Kim, ST; Lee, J; Kang, WK; Han, H; Sohn, I; Kim, KM
    View PubMed
  • Am J Transl Res 2019 Neutralizing antibody to FGFR2 can act as a selective biomarker and potential therapeutic agent for gastric cancer with FGFR2 amplification Kim1, ST; Lee, IK; Rom, E; Sirkis, R; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, KM; Yayon, A; Lee, J
    View PubMed
  • CANCER RES TREAT 2019 10.4143/crt.2018.379 A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients Kim1, Y; Kim, TW; Han, SW; Ahn, JB; Kim, ST; Lee, J; Park, JO; Park, YS; Lim, HY; Kang, WK
    View PubMed
  • CANCER RES TREAT 2019 10.4143/crt.2018.401 Comparison of the 7th and the 8th AJCC Staging System for Non-metastatic D2-Resected Lymph Node-Positive Gastric Cancer Treated with Different Adjuvant Protocols Yu1, JI; Lim, D; Lee, J; Kang, WK; Park, SH; Park, JO; Park, YS; Lim, HY; Kim, ST; Lee, SJ; Kim, S; Sohn, TS; Lee, JH; An, JY; Choi, MG; Rae, JM; Yoo, H; Kim, K
    View PubMed
  • J Cancer 2019 10.7150/jca.30355 The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma Yoon1, SE; Kim, JH; Lee, SJ; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS; Kim, ST
    View PubMed
  • J Cancer 2019 10.7150/jca.30257 High delta-like ligand 4 expression correlates with a poor clinical outcome in gastric cancer Kim1, Y; Byeon, SJ; Hur, J; Lee, K; Kim, D; Ahn, JH; Lee, SH; You, WK; Kim, ST; Park, SH; Kang, WK; Kim, KM; Lee, J
    View PubMed
  • ANN ONCOL 2019 10.1093/annonc/mdz058 Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial Kim1, ST; Kang, JH; Lee, J; Lee, HW; Oh, SY; Jang, JS; Lee, MA; Sohn, BS; Yoon, SY; Choi, HJ; Hong, JH; Kim, MJ; Kim, S; Park, YS; Park, JO; Lim, HY
    View PubMed
  • ONCOLOGY-BASEL 2019 10.1159/000499628 Prognostic Impact of Microsatellite Instability in Asian Gastric Cancer Patients Enrolled in the ARTIST Trial Miceli1, R; An, J; Di Bartolomeo, M; Morano, F; Kim, ST; Park, SH; Choi, MG; Lee, JH; Raimondi, A; Fuca, G; Sohn, TS; Bae, JM; Kim, S; Lim, DH; Kang, WK; Kim, KM; Pietrantonio, F; Lee, J
    View PubMed
  • PLoS One 2019 10.1371/journal.pone.0215080 Selective colony area method for heterogeneous patient-derived tumor cell lines in anti-cancer drug screening system Cho1, JH; Kim, JS; Kim, ST; Hong, JY; Park, JO; Park, YS; Nam, DH; Lee, DW; Lee, J
    View PubMed
  • TRANSL ONCOL 2019 10.1016/j.tranon.2018.12.009 Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial Kim1, ST; Lee, S; Park, M; Park, SH; Park, JO; Lim, HY; Park, YS; Kang, WK; Gangolli, EA; Shin, H; Kim, KM; Hollingsworth, SJ; Mortimer, PGS; Lee, J
    View PubMed
  • Front Oncol 2019 10.3389/fonc.2019.00212 Detection of ERBB2 (HER2) Gene Amplification Events in Cell-Free DNA and Response to Anti-HER2 Agents in a Large Asian Cancer Patient Cohort Lee1, J; Franovic, A; Shiotsu, Y; Kim, ST; Kim, KM; Banks, KC; Raymond, VM; Lanman, RB
    View PubMed
  • CANCER CHEMOTH PHARM 2019 10.1007/s00280-018-3753-y Safety and efficacy of trastuzumab administered as a 30-min infusion in patients with HER2-positive advanced gastric cancer Oh1, SY; Lee, S; Huh, SJ; Lee, J; Kim, ST; Park, SH; Lim, HY; Kang, WK; Kang, BW; Kim, JG; Lee, HJ; Kim, JH; Kang, JH; Kim, H
    View PubMed
  • PATHOL RES PRACT 2019 10.1016/j.prp.2018.11.010 MET is overexpressed in microsatellite instability-high gastric carcinoma Sim1, J; Heo, YJ; Bae, H; Shin, HC; Kim, B; Cho, J; Kim, ST; Lee, J; Kang, WK; Kim, KM
    View PubMed
  • ANN ONCOL 2019 10.1093/annonc/mdy550 Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer Sundar1, R; Huang, KK; Qamra, A; Kim, KM; Kim, ST; Kang, WK; Tan, ALK; Lee, J; Tan, P
    View PubMed
  • J Cancer 2019 10.7150/jca.29106 The Impact of Primary Tumor Sidedness on the Effect of Regorafenib in Refractory Metastatic Colorectal Cancer Yoon1, SE; Lee, SJ; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS; Kim, ST
    View PubMed
  • Oncoimmunology 2019 10.1080/2162402X.2018.1544442 PD-L1 and immune infiltrates are differentially expressed in distinct subgroups of gastric cancer Angell1, HK; Lee, J; Kim, KM; Kim, K; Kim, ST; Park, SH; Kang, WK; Sharpe, A; Ogden, J; Davenport, A; Hodgson, DR; Barrett, JC; Kilgour, E
    View PubMed
  • OncoTargets and therapy 2019 10.2147/OTT.S187621 The use of regorafenib for patients with refractory metastatic colorectal cancer in clinical practice Yoon1, SE; Lee, SJ; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS; Kim, ST
    View PubMed
  • J Gastric Cancer 2018 10.5230/jgc.2018.18.e34 Adjuvant Chemotherapy with or without Concurrent Radiotherapy for Patients with Stage IB Gastric Cancer: a Subgroup Analysis of the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Phase III Trial Kim1, Y; Kim, KM; Choi, MG; Lee, JH; Sohn, TS; Bae, JM; Kim, S; Lee, SJ; Kim, ST; Lee, J; Park, JO; Park, YS; Lim, HY; Kang, WK; Park, SH
    View PubMed
  • SCI REP-UK 2018 10.1038/s41598-018-34858-x SEPROGADIC-serum protein-based gastric cancer prediction model for prognosis and selection of proper adjuvant therapy Ahn1, HS; Sohn, TS; Kim, MJ; Cho, BK; Kim, SM; Kim, ST; Yi, EC; Lee, C
    View PubMed
  • RADIOTHER ONCOL 2018 10.1016/j.radonc.2018.07.002 Necessity of adjuvant concurrent chemo-radiotherapy in D2-resected LN-positive gastric cancer Yu1, JI; Lim, DH; Lee, J; Kang, WK; Park, SH; Park, JO; Park, YS; Lim, HY; Kim, ST; Lee, SJ; Kim, S; Sohn, TS; Lee, JH; An, JY; Choi, MG; Bae, JM; Kim, HS; Ahn, S
    View PubMed
  • BMC CANCER 2018 10.1186/s12885-018-4995-0 Triptolide as a novel agent in pancreatic cancer: the validation using patient derived pancreatic tumor cell line Kim1, ST; Kim, SY; Lee, J; Kim, K; Park, SH; Park, YS; Lim, HY; Kang, WK; Park, JO
    View PubMed
  • NAT GENET 2018 10.1038/s41588-018-0209-6 Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy Lee1, JK; Liu, ZQ; Sa, JK; Shin, S; Wang, JG; Bordyuh, M; Cho, H; Elliott, O; Chu, T; Choi, SW; Rosenbloom, DIS; Lee, IH; Shin, YJ; Kang, HJ; Kim, D; Kim, SY; Sim, MH; Kim, J; Lee, T; Seo, YJ; Shin, H; Lee, M; Kim, SH; Kwon, YJ; Oh, JW; Song, M; Kim, M; Kong, DS; Choi, JW; Seol, HJ; Lee, JI; Kim, ST; Park, JO; Kim, KM; Song, SY; Lee, JW; Kim, HC; Lee, JE; Choi, MG; Seo, SW; Shim, YM; Zo, JI; Jeong, BC; Yoon, Y; Ryu, GH; Kim, NKD; Bae, JS; Park, WY; Lee, J; Verhaak, RGW; Iavarone, A; Lee, J; Rabadan, R; Nam, DH
    View PubMed
  • J Cancer 2018 10.7150/jca.26068 Antitumor activity of sorafenib plus CDK4/6 inhibitor in pancreatic patient derived cell with KRAS mutation Lee1, T; Kim, K; Lee, J; Park, SH; Park, YS; Lim, HY; Kang, WK; Park, JO; Kim, ST
    View PubMed
  • NAT MED 2018 10.1038/s41591-018-0101-z Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer Kim1, ST; Cristescu, R; Bass, AJ; Kim, KM; Odegaard, JI; Kim, K; Liu, XQ; Sher, XW; Jung, H; Lee, M; Lee, S; Park, SH; Park, JO; Park, YS; Lim, HY; Lee, H; Choi, M; Talasaz, A; Kang, PS; Cheng, J; Loboda, A; Lee, J; Kang, WK
    View PubMed
  • CLIN COLORECTAL CANC 2018 10.1016/j.clcc.2018.02.013 c-MET Overexpression in Colorectal Cancer: A Poor Prognostic Factor for Survival Lee1, SJ; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS; Kim, ST
    View PubMed
  • J Cancer 2018 10.7150/jca.24948 Pemetrexed Monotherapy as Salvage Treatment in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy: A Phase II Single-arm Prospective Trial Lim1, SW; Lee, S; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST
    View PubMed
  • J Cancer 2018 10.7150/jca.26256 NCOA4-RET fusion in colorectal cancer: Therapeutic challenge using patient-derived tumor cell lines Kim1, SY; Oh, SO; Kim, K; Lee, J; Kang, S; Kim, KM; Lee, W; Kim, ST; Nam, DN
    View PubMed
  • CLIN COLORECTAL CANC 2018 10.1016/j.clcc.2018.01.005 Phase I Trial of Anti-MET Monoclonal Antibody in MET-Overexpressed Refractory Cancer Lee1, J; Kim, ST; Park, S; Lee, S; Park, SH; Park, JO; Lim, HY; Ahn, H; Bok, H; Kim, KM; Ahn, MJ; Kang, WK; Park, YS
    View PubMed
  • ANN ONCOL 2018 10.1093/annonc/mdy090 RET fusions in a small subset of advanced colorectal cancers at risk of being neglected Pietrantonio1, F; Di Nicolantonio, F; Schrock, AB; Lee, J; Morano, F; Fuca, G; Nikolinakos, P; Drilon, A; Hechtman, JF; Christiansen, J; Gowen, K; Frampton, GM; Gasparini, P; Rossini, D; Gigliotti, C; Kim, ST; Prisciandaro, M; Hodgson, J; Zaniboni, A; Chiu, VK; Milione, M; Patel, R; Miller, V; Bardelli, A; Novara, L; Wang, L; Pupa, SM; Sozzi, G; Ross, J; Di Bartolomeo, M; Bertotti, A; Ali, S; Trusolino, L; Falcone, A; de Braud, F; Cremolini, C
    View PubMed
  • TRANSL ONCOL 2018 10.1016/j.tranon.2018.01.007 The Correlation Between Serum Chemokines and Clinical Outcome in Patients with Advanced Biliary Tract Cancer Lee1, SJ; Kim, JE; Kim, ST; Lee, J; Park, SH; Park, JO; Kang, WK; Park, YS; Lim, HY
    View PubMed
  • ANN ONCOL 2018 10.1093/annonc/mdy034 Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+gastric cancer patients Kim1, ST; Banks, KC; Pectasides, F; Kim, SY; Kim, K; Lanman, RB; Talasaz, A; An, J; Choi, MG; Lee, JH; Sohn, TS; Bae, JM; Kim, S; Park, SH; Park, JO; Park, YS; Lim, HY; Kim, NKD; Park, W; Lee, H; Bass, AJ; Kim, K; Kang, WK; Lee, J
    View PubMed
  • J Cancer 2018 10.7150/jca.25132 The impact of microsatellite instability status and sidedness of the primary tumor on the effect of bevacizumab-containing chemotherapy in patients with metastatic colorectal cancer Kim1, ST; Kim, HK; Lee, J; Park, SH; Lim, HY; Park, YS; Kang, WK; Park, JO
    View PubMed
  • ONCOLOGIST 2018 10.1634/theoncologist.2017-0528 Phase I Pharmacokinetic Study of Nivolumab in Korean Patients with Advanced Solid Tumors Lee1, KW; Lee, DH; Kang, JH; Park, JO; Kim, SH; Hong, YS; Kim, ST; Oh, DY; Bang, YJ
    View PubMed
  • J NATL CANCER I 2017 10.1093/jnci/djx089 ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer Pietrantonio1, F; Di Nicolantonio, F; Schrock, AB; Lee, J; Tejpar, S; Sartore-Bianchi, A; Hechtman, JF; Christiansen, J; Novara, L; Tebbutt, N; Fuca, G; Antoniotti, C; Kim, ST; Murphy, D; Berenato, R; Morano, F; Sun, J; Min, BS; Stephens, PJ; Chen, M; Cremolini, C
    View PubMed
  • ONCOTARGET 2017 10.18632/oncotarget.22394 MerTK inhibition by RXDX-106 in MerTK activated gastric cancer cell lines Kim1, JE; Kim, Y; Li, G; Kim, ST; Kim, K; Park, SH; Park, JO; Park, YS; Lim, HY; Lee, H; Sohn, TS; Kim, KM; Kang, WK; Lee, J
    View PubMed
  • ONCOTARGET 2017 10.18632/oncotarget.18182 Correlation between MEK signature and Ras gene alteration in advanced gastric cancer Ahn1, S; Brant, R; Sharpe, A; Dry, JR; Hodgson, DR; Kilgour, E; Kim, K; Kim, ST; Park, SH; Kang, WK; Kim, KM; Lee, J
    View PubMed
  • ONCOLOGIST 2017 10.1634/theoncologist.2017-0129 Antiemetic Corticosteroid Rotation from Dexamethasone to Methylprednisolone to Prevent Dexamethasone-Induced Hiccup in Cancer Patients Treated with Chemotherapy: A Randomized, Single-Blind, Crossover Phase III Trial Go1, SI; Koo, DH; Kim, ST; Song, HN; Kim, RB; Jang, JS; Oh, SY; Lee, KH; Lee, SI; Kim, SG; Park, LC; Lee, SC; Park, BB; Ji, JH; Yi, SY; Lee, YG; Yun, J; Bruera, E; Hwang, IG; Kang, JH
    View PubMed
  • NAT COMMUN 2017 10.1038/s41467-017-01470-y Prevalence and detection of low-allele-fraction variants in clinical cancer samples Shin1, HT; Choi, YL; Yun, JW; Kim, NKD; Kim, SY; Jeon, HJ; Nam, JY; Lee, C; Ryu, D; Kim, SC; Park, K; Lee, E; Bae, JS; Son, DS; Joung, JG; Lee, J; Kim, ST; Ahn, MJ; Lee, SH; Ahn, JS; Lee, WY; Oh, BY; Park, YH; Lee, JE; Lee, KH; Kim, HC; Kim, KM; Im, YH; Park, K; Park, PJ; Park, WY
    View PubMed
  • ONCOTARGET 2017 10.18632/oncotarget.3750 MerTK is a novel therapeutic target in gastric cancer Yi1, JH; Jang, J; Cho, J; Do, IG; Hong, M; Kim, ST; Kim, KM; Lee, S; Park, SH; Park, JO; Park, YS; Kang, WK; Lim, HY; Lee, J
    View PubMed
  • Oncoimmunology 2017 10.1080/2162402X.2017.1356150 Host immune response index in gastric cancer identified by comprehensive analyses of tumor immunity Park1, C; Cho, J; Lee, J; Kang, SY; An, JY; Choi, MG; Lee, JH; Sohn, TS; Bae, JM; Kim, S; Kim, ST; Park, SH; Park, JO; Kang, WK; Sohn, I; Jung, SH; Kang, MS; Kim, KM
    View PubMed
  • Clin Transl Oncol 2017 10.1007/s12094-017-1662-x Emergence of CTNNB1 mutation at acquired resistance to KIT inhibitor in metastatic melanoma Cho1, J; Kim, SY; Kim, YJ; Sim, MH; Kim, ST; Kim, NKD; Kim, K; Park, W; Kim, JH; Jang, KT; Lee, J
    View PubMed
  • ONCOLOGIST 2017 10.1634/theoncologist.2017-0020 Clinical Application of Targeted Deep Sequencing in Solid-Cancer Patients and Utility for Biomarker-Selected Clinical Trials Kim1, ST; Kim, KM; Kim, NKD; Park, JO; Ahn, S; Yun, JW; Kim, KT; Park, SH; Park, PJ; Kim, HC; Sohn, TS; Il Choi, D; Cho, JH; Heo, JS; Kwon, W; Lee, H; Min, BH; Hong, SN; Park, YS; Lim, HY; Kang, WK; Park, WY; Lee, J
    View PubMed
  • ONCOTARGET 2017 10.18632/oncotarget.18168 The impact of pathologic differentiation (well/poorly) and the degree of Ki-67 index in patients with metastatic WHO grade 3 GEP-NECs Kim1, HK; Ha, SY; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS; Kim, ST
    View PubMed
  • ONCOTARGET 2017 10.18632/oncotarget.20492 Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy Kim1, ST; Klempner, SJ; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, KM; Lee, J
    View PubMed
  • ONCOTARGET 2017 10.18632/oncotarget.19985 Development of mesenchymal subtype gene signature for clinical application in gastric cancer Lee1, J; Cristescu, R; Kim, KM; Kim, K; Kim, ST; Park, SH; Kang, WK
    View PubMed
  • J Cancer 2017 10.7150/jca.19458 The Impact of Cetuximab Plus AKT- or mTOR-Inhibitor in a Patient-Derived Colon Cancer Cell Model with Wild-Type RAS and PIK3CA Mutation Kim1, JS; Kim, JE; Kim, K; Lee, J; Park, JO; Lim, HY; Park, YS; Kang, WK; Kim, ST
    View PubMed
  • J Cancer 2017 10.7150/jca.18286 The Impact of Microsatellite Instability Status and Sidedness of the Primary Tumor on the Effect of Cetuximab-Containing Chemotherapy in Patients with Metastatic Colorectal Cancer Kim1, ST; Lee, SJ; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS
    View PubMed
  • J Cancer 2017 10.7150/jca.19582 MAP2K1 Mutation in Colorectal Cancer Patients: Therapeutic Challenge Using Patient-Derived Tumor Cell Lines Kim1, JE; Kim, KK; Kim, SY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST
    View PubMed
  • EUR RADIOL 2017 10.1007/s00330-016-4644-4 Disappearing or residual tiny (ae<currency>5 mm) colorectal liver metastases after chemotherapy on gadoxetic acid-enhanced liver MRI and diffusion-weighted imaging: Is local treatment required? Kim1, SS; Song, KD; Kim, YK; Kim, HC; Huh, JW; Park, YS; Park, JO; Kim, ST
    View PubMed
  • TUMORI 2017 10.5301/tj.5000666 Clinical outcomes of salvage chemoradiotherapy for locally recurrent biliary tract cancer Yu1, JI; Park, HC; Lim, DH; Park, JO; Park, YS; Kim, ST; Choi, SH; Choi, DW; Han, IW; Heo, JS
    View PubMed
  • BMC Cancer. 2017 Mar 23;17(1):211. doi: 10.1186/s12885-017-3196-6. Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy Kim ST11, Lee J1, Park SH1, Park JO1, Park YS1, Kang WK1, Lim HY2.
    View PubMed
  • Ann Oncol. 2017 Mar 1;28(3):547-554. doi: 10.1093/annonc/mdw669. Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition Kim ST11, Kim SY1, Klempner SJ2,3, Yoon J4, Kim N4, Ahn S4,5, Bang H5,6, Kim KM5,6, Park W4, Park SH1, Park JO1, Park YS1, Lim HY1, Lee SH1, Park K1,6, Kang WK1, Lee J1.
    View PubMed
  • Oncotarget. 2017 Feb 14;8(7):11094-11104. doi: 10.18632/oncotarget.14362. Direct analysis of aberrant glycosylation on haptoglobin in patients with gastric cancer Kim JH11, Lee SH2, Choi S2, Kim U3, Yeo IS4, Kim SH2, Oh MJ3, Moon H3, Lee J3, Jeong S3, Choi MG5, Lee JH5, Sohn TS5, Bae JM5, Kim S5, Min YW5, Lee H5, Lee JH5, Rhee PL5, Kim JJ5, Lee SJ5, Kim ST5, Lee J5, Park SH5, Park JO5, Park YS5, Lim HY5, Kang WK5, An HJ3, Kim JH4.
    View PubMed
  • Oncotarget. 2017 Feb 28;8(9):15014-15022. doi: 10.18632/oncotarget.14788. Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion Kim SY11, Ahn T2, Bang H3, Ham JS1, Kim J1, Kim ST1, Jang J1, Shim M1, Kang SY3, Park SH1, Min BH4, Lee H4, Kang WK1, Kim KM3, Park W2,5, Lee J1.
    View PubMed
  • Oncotarget. 2017 Feb 21;8(8):13320-13328. doi: 10.18632/oncotarget.14519. Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability Cho J11, Lee J2, Bang H3, Kim ST2, Park SH2, An JY4, Choi MG4, Lee JH4, Sohn TS4, Bae JM4, Kang WK2, Kim S4, Kim KM3.
    View PubMed
  • Oncotarget. 2017 Jan 10;8(2):3237-3245. doi: 10.18632/oncotarget.13700. The implication of FLT3 amplification for FLT targeted therapeutics in solid tumors Lim SH11, Kim SY1, Kim K2, Jang H1, Ahn S2, Kim KM2, Kim NK3, Park W3, Lee SJ1, Kim ST1, Park SH1, Park JO1, Park YS1, Lee SH1, Lim HY1, Park K1, Kang WK1, Lee J1.
    View PubMed
  • Am J Ther. 2016 Nov/Dec;23(6):e1449-e1455. A Prognostic Index to Identify Patients With Intrahepatic Cholangiocarcinoma Who Could Benefit From Gemcitabine Plus Cisplatin Lee SY11, Kim HS, Choi YJ, Park KH, Shin SW, Kim YH, Tae Kim S.
    View PubMed
  • J Cancer. 2016 Oct 25;7(15):2173-2178. eCollection 2016. To Excavate Biomarkers Predictive of the Response for Capecitabine plus RAD001 through Nanostring-Based Multigene Assay in Advanced Gastric Cancer Patients Lee H11, Lee J2, Sohn I3, Park SH2, Park JO2, Park YS2, Kim KM4, Kang WK2, Kim ST2.
    View PubMed
  • Transl Oncol. 2016 Oct;9(5):466-471. doi: 10.1016/j.tranon.2016.08.009. Loss of Tuberous Sclerosis Complex 2 (TSC2) as a Predictive Biomarker of Response to mTOR Inhibitor Treatment in Patients with Hepatocellular Carcinoma Cho J11, Lee J1, Kim J1, Kim ST1, Lee S1, Kim SY1, Ha SY2, Park CK3, Lim HY4.
    View PubMed
  • Oncotarget. 2016 Sep 20;7(38):62676-62686. doi: 10.18632/oncotarget.10445. Prognostic significance of survivin in rectal cancer patients treated with surgery and postoperative concurrent chemo-radiation therapy Yu JI11, Lee H2, Park HC1, Choi DH1, Choi YL3, Do IG4, Kim HC5, Lee WY5, Yun SH5, Cho YB5, Huh JW5, Park YA6, Park YS6, Park JO6, Kim ST6, Park W1.
    View PubMed
  • Mod Pathol. 2016 Sep;29(9):1095-103. doi: 10.1038/modpathol.2016.96. Epub 2016 May 27. FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival Ahn S11,2, Lee J3, Hong M4, Kim ST3, Park SH3, Choi MG5, Lee JH5, Sohn TS5, Bae JM5, Kim S5, Jung SH6, Kang WK3, Kim KM1,2.
    View PubMed
  • Mol Diagn Ther. 2016 Aug;20(4):375-83. doi: 10.1007/s40291-016-0205-4. A nCounter CNV Assay to Detect HER2 Amplification: A Correlation Study with Immunohistochemistry and In Situ Hybridization in Advanced Gastric Cancer Ahn S11,2, Hong M3, Van Vrancken M4, Lyou YJ2, Kim ST5, Park SH5, Kang WK5, Park YS5, Jung SH6, Woo M6, Lee J7, Kim KM8,9.
    View PubMed
  • Onco Targets Ther. 2016 Jun 1;9:3307-12. doi: 10.2147/OTT.S104511. eCollection 2016. The prognostic role of serum C-X-C chemokine receptor type 4 in patients with metastatic or recurrent colorectal cancer Choi YJ11, Chang WJ1, Shin SW1, Park KH1, Kim ST2, Kim YH1.
    View PubMed
  • Transl Oncol. 2016 Jun;9(3):173-8. doi: 10.1016/j.tranon.2016.01.007. Epub 2016 Apr 22. Genomic Alterations in Biliary Tract Cancer Using Targeted Sequencing Yoo KH11, Kim NK2, Kwon WI3, Lee C2, Kim SY1, Jang J1, Ahn J1, Kang M1, Jang H1, Kim ST1, Ahn S4, Jang KT4, Park YS1, Park WY5, Lee J6, Heo JS7, Park JO8.
    View PubMed
  • Transl Oncol. 2016 Jun;9(3):197-202. doi: 10.1016/j.tranon.2016.03.008. Epub 2016 May 12. BEZ235 (PIK3/mTOR inhibitor) Overcomes Pazopanib Resistance in Patient-Derived Refractory Soft Tissue Sarcoma Cells Kim HK11, Kim SY1, Lee SJ1, Kang M1, Kim ST1, Jang J1, Rath O2, Schueler J2, Lee DW3, Park WY4, Kim SJ5, Park SH1, Lee J6.
    View PubMed
  • J Cancer Res Clin Oncol. 2016 Jun;142(6):1231-7. doi: 10.1007/s00432-016-2143-2. Epub 2016 Mar 16. Value of FGFR2 expression for advanced gastric cancer patients receiving pazopanib plus CapeOX (capecitabine and oxaliplatin) Kim ST11, Ahn S2, Lee J1, Lee SJ1, Park SH1, Park YS1, Lim HY1, Kang WK1, Kim KM2, Park JO3.
    View PubMed
  • Medicine (Baltimore). 2016 May;95(19):e3534. doi: 10.1097/MD.0000000000003534. The Clinicopathologic Features and Treatment of 607 Hindgut Neuroendocrine Tumor (NET) Patients at a Single Institution Kim ST11, Ha SY, Lee J, Hong SN, Chang DK, Kim YH, Park YA, Huh JW, Cho YB, Yun SH, Lee WY, Kim HC, Park YS.
    View PubMed
  • J Cancer. 2016 May 25;7(9):1044-8. doi: 10.7150/jca.14815. eCollection 2016. Genomic Profiling of Metastatic Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients in the Personalized-Medicine Era Kim ST11, Lee SJ1, Park SH1, Park JO1, Lim HY1, Kang WK1, Lee J1, Park YS1.
    View PubMed
  • Cancer Chemother Pharmacol. 2016 May;77(5):979-85. doi: 10.1007/s00280-016-3014-x. Epub 2016 Mar 26. Role of adjuvant therapy after R0 resection for patients with distal cholangiocarcinoma Kim YS11, Hwang IG2, Park SE3, Go SI4, Kang JH4, Park I1, Oh SY5, Ji JH6, Song HN7, Park SH7, Kim ST7, Park JO7.
    View PubMed
  • Cancer Res Treat. 2016 Apr;48(2):553-60. doi: 10.4143/crt.2015.155. Epub 2015 Aug 10. A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology Yi JH11, Kang JH2, Hwang IG3, Ahn HK4, Baek HJ5, Lee SI5, Lim DH5, Won YW6, Ji JH7, Kim HS8, Rha SY8, Oh SY9, Lee KE10, Lim T11, Maeng CH12, Kim MJ13, Kim ST13, Lee J13, Park JO13, Park YS13, Lim HY13, Kang WK13, Park SH13.
    View PubMed
  • Oncotarget. 2016 Apr 26;7(17):24088-96. doi: 10.18632/oncotarget.8175. Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer Kim ST11, Lee J1, Lee SJ1, Park SH1, Jung SH2, Park YS1, Lim HY1, Kang WK1, Park JO1.
    View PubMed
  • Oncotarget. 2016 Apr 12;7(15):19610-9. doi: 10.18632/oncotarget.7526. Molecular characterization of colorectal cancer patients and concomitant patient-derived tumor cell establishment Song HN11,2, Lee C3,4, Kim ST1, Kim SY1, Kim NK3, Jang J1, Kang M1, Jang H1, Ahn S5, Kim SH5, Park Y6, Cho YB6, Heo JW6, Lee WY6, Park JO1, Lim HY1, Kang WK1, Park YS1, Park WY3,7,4, Lee J1, Kim HC6.
    View PubMed
  • BMC Cancer. 2016 Feb 18;16:120. doi: 10.1186/s12885-016-2141-4. The impact of KRAS mutations on prognosis in surgically resected colorectal cancer patients with liver and lung metastases: a retrospective analysis Kim HS11,2, Heo JS3, Lee J4, Lee JY5, Lee MY6, Lim SH7, Lee WY8, Kim SH9, Park YA10, Cho YB11, Yun SH12, Kim ST13, Park JO14, Lim HY15, Choi YS16, Kwon WI17, Kim HC18, Park YS19.
    View PubMed
  • J Cancer. 2016 Feb 5;7(5):484-9. doi: 10.7150/jca.13711. eCollection 2016. The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs Kim ST11, Ha SY2, Lee S1, Ahn S2, Lee J1, Park SH1, Park JO1, Lim HY1, Kang WK1, Kim KM2, Park YS1.
    View PubMed
  • Oncotarget. 2016 Jan 26;7(4):4024-35. doi: 10.18632/oncotarget.6602. Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors Park C11, Ha SY1, Kim ST2, Kim HC3, Heo JS3, Park YS2, Lauwers G4, Lee J2, Kim KM1.
    View PubMed
  • Cancer Res Treat. 2016 Jan;48(1):153-61. doi: 10.4143/crt.2014.183. Epub 2015 Mar 7. The Role of Plasma Chromogranin A as Assessment of Treatment Response in Non-functioning Gastroenteropancreatic Neuroendocrine Tumors Kim M11, Lee S2, Lee J2, Park SH2, Park JO2, Park YS2, Kang WK2, Kim ST2.
    View PubMed
  • Oncotarget. 2015 Nov 24;6(37):40360-9. doi: 10.18632/oncotarget.5465. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients Kim ST11, Lee WS2, Lanman RB3, Mortimer S3, Zill OA3, Kim KM4,5, Jang KT5, Kim SH5, Park SH1, Park JO1,4, Park YS1, Lim HY1, Eltoukhy H3, Kang WK1, Lee WY6, Kim HC6, Park K1,4, Lee J1,4, Talasaz A3.
    View PubMed
  • Br J Cancer. 2015 Nov 17;113(10):1421-6. doi: 10.1038/bjc.2015.371. Epub 2015 Oct 27. A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer Lim SH11, Kim TW2, Hong YS2, Han SW3, Lee KH3, Kang HJ4, Hwang IG5, Lee JY1, Kim HS1, Kim ST1, Lee J1, Park JO1, Park SH1, Park YS1, Lim HY1, Jung SH6,7, Kang WK1.
    View PubMed
  • Oncotarget. 2015 Nov 17;6(36):39028-35. doi: 10.18632/oncotarget.5494. NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line Lee SJ11, Li GG2, Kim ST1, Hong ME3, Jang J1, Yoon N3, Ahn SM3, Murphy D2, Christiansen J2, Wei G2, Hornby Z2, Lee DW4, Park JO1,5, Park YS1, Lim HY1, Hong SN6, Kim SH3, Kang WK1, Park K1, Park WY7, Kim KM3,5, Lee J1.
    View PubMed
  • Oncotarget. 2015 Nov 24;6(37):40026-35. doi: 10.18632/oncotarget.5432. PIK3CA mutation detection in metastatic biliary cancer using cell-free DNA Kim ST11, Lira M2, Deng S2, Lee S1, Park YS1, Lim HY1, Kang WK1, Mao M3, Heo JS4, Kwon W4, Jang KT5, Lee J1,6, Park JO1,6.
    View PubMed
  • Radiother Oncol. 2015 Oct;117(1):171-7. doi: 10.1016/j.radonc.2015.08.009. Epub 2015 Aug 20. Effects of adjuvant radiotherapy on completely resected gastric cancer: A radiation oncologist's view of the ARTIST randomized phase III trial Yu JI11, Lim do H2, Ahn YC1, Lee J3, Kang WK3, Park SH3, Park JO3, Park YS3, Lim HY3, Kim ST3, Kim S4, Sohn TS4, Choi MG4, Bae JM4, Nam H5.
    View PubMed
  • Int J Biol Markers. 2015 Nov 11;30(4):e382-6. doi: 10.5301/jbm.5000151. Circulating tumor cells are predictive of poor response to chemotherapy in metastatic gastric cancer Lee SJ11, Lee J1, Kim ST1, Park SH1, Park JO1, Park YS1, Lim HY1, Kang WK1.
    View PubMed
  • BMC Cancer. 2015 Oct 20;15:747. doi: 10.1186/s12885-015-1759-y. Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan Kim ST1, Ahn TJ, Lee E, Do IG, Lee SJ, Park SH, Park JO, Park YS, Lim HY, Kang WK, Kim SH, Lee J, Kim HC
    View PubMed
  • J Clin Oncol. 2015 Oct 1;33(28):3130-6. doi: 10.1200/JCO.2014.58.3930. Epub 2015 Jan 5. Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses Park SH11, Sohn TS1, Lee J1, Lim DH1, Hong ME1, Kim KM1, Sohn I1, Jung SH1, Choi MG1, Lee JH1, Bae JM1, Kim S1, Kim ST1, Park JO1, Park YS1, Lim HY1, Kang WK2.
    View PubMed
  • Cancer Res Treat. 2015 Oct;47(4):790-5. doi: 10.4143/crt.2014.126. Epub 2014 Dec 2. Regorafenib as Salvage Treatment in Korean Patients with Refractory Metastatic Colorectal Cancer Kim ST11, Kim TW2, Kim KP2, Kim TY3, Han SW3, Lee JY1, Lim SH1, Lee MY1, Kim H1, Park YS1.
    View PubMed
  • Oncotarget. 2015 Oct 20;6(32):33358-68. doi: 10.18632/oncotarget.5188. The NEXT-1 (Next generation pErsonalized tX with mulTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis Kim ST11, Lee J1, Hong M2,3, Park K4,5, Park JO1, Ahn T3,4, Park SH1, Park YS1, Lim HY1, Sun JM1, Ahn JS1, Ahn MJ1, Kim HC6, Sohn TS6, Choi DI7, Cho JH8, Heo JS6, Kwon W6, Uhm SW9, Lee H10, Min BH10, Hong SN10, Kim DH5,11, Jung SH12, Park W4,5, Kim KM2,3, Kang WK1, Park K1,2.
    View PubMed
  • Cancer Res Treat. 2015 Oct;47(4):796-803. doi: 10.4143/crt.2014.106. Epub 2015 Jan 30. Can Serum be Used for Analyzing the KRAS Mutation Status in Patients with Advanced Colorectal Cancer Kim ST11,2, Chang WJ1, Jin L3, Sung JS3, Choi YJ1, Kim YH1,3.
    View PubMed
  • Oncotarget. 2015 Sep 29;6(29):28211-22. doi: 10.18632/oncotarget.4721. Gastrointestinal malignancies harbor actionable MET exon 14 deletions Lee J11,2, Ou SH3, Lee JM4, Kim HC5, Hong M6, Kim SY1, Jang J1, Ahn S6, Kang SY6, Lee S1, Kim ST1, Kim B4, Choi J4, Kim KA4, Lee J1, Park C1,6, Park SH1, Park JO1,2, Lim HY1, Kang WK1, Park K1,2, Park YS1, Kim KM2,6.
    View PubMed
  • Oncotarget. 2015 Sep 15;6(27):24320-32. Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening Lee J11, Kim HC2, Hong JY3, Wang K4, Kim SY1, Jang J1, Kim ST1, Park JO1, Lim HY1, Kang WK1, Park YS1, Lee J1, Lee WY2, Park YA2, Huh JW2, Yun SH2, Do IG5, Kim SH5, Balasubramanian S4, Stephens PJ4, Ross JS4,6, Li GG7, Hornby Z7, Ali SM4, Miller VA4, Kim KM5,8, Ou SH9.
    View PubMed
  • Oncotarget. 2015 Sep 22;6(28):25619-30. doi: 10.18632/oncotarget.4627. Patient-derived cell models as preclinical tools for genome-directed targeted therapy Lee JY11, Kim SY1, Park C1, Kim NK2, Jang J1, Park K2, Yi JH3, Hong M4,5, Ahn T2, Rath O6, Schueler J6, Kim ST1, Do IG5, Lee S1, Park SH1, Ji YI7, Kim D7, Park JO1,4, Park YS1, Kang WK1, Kim KM4,5, Park WY2,7, Lim HY1, Lee J1,4.
    View PubMed
  • Transl Oncol. 2015 Aug;8(4):288-94. doi: 10.1016/j.tranon.2015.06.001. Clinical Significance of IGFBP-3 Methylation in Patients with Early Stage Gastric Cancer Kim ST11, Jang HL2, Lee J1, Park SH1, Park YS1, Lim HY1, Choi MG3, Bae JM3, Sohn TS3, Noh JH3, Kim S3, Kim KM4, Kang WK1, Park JO5.
    View PubMed
  • BMC Cancer. 2015 Jul 21;15:530. doi: 10.1186/s12885-015-1552-y. Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer Kim ST11, Jang KT2, Lee SJ3, Jang HL4, Lee J5, Park SH6, Park YS7, Lim HY8, Kang WK9, Park JO10.
    View PubMed
  • Clin Transl Oncol. 2015 Jun;17(6):462-8. doi: 10.1007/s12094-014-1258-7. Epub 2014 Dec 2. The NanoString-based multigene assay as a novel platform to screen EGFR, HER2, and MET in patients with advanced gastric cancer Kim ST11, Do IG, Lee J, Sohn I, Kim KM, Kang WK.
    View PubMed
  • Nat Med. 2015 May;21(5):449-56. doi: 10.1038/nm.3850. Epub 2015 Apr 20. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes Cristescu R11, Lee J2, Nebozhyn M1, Kim KM3, Ting JC4, Wong SS4, Liu J4, Yue YG4, Wang J4, Yu K4, Ye XS4, Do IG3, Liu S5, Gong L5, Fu J6, Jin JG6, Choi MG7, Sohn TS7, Lee JH7, Bae JM7, Kim ST2, Park SH2, Sohn I8, Jung SH8, Tan P9, Chen R1, Hardwick J1, Kang WK2, Ayers M1, Hongyue D1, Reinhard C4, Loboda A1, Kim S7, Aggarwal A4.
    View PubMed
  • Sci Rep. 2015 Mar 19;5:9289. doi: 10.1038/srep09289. The Impact of Concomitant Genomic Alterations on Treatment Outcome for Trastuzumab Therapy in HER2-Positive Gastric Cancer Lee JY11, Hong M2, Kim ST1, Park SH1, Kang WK1, Kim KM2, Lee J1.
    View PubMed
  • Transl Oncol. 2015 Feb;8(1):40-6. doi: 10.1016/j.tranon.2014.12.003. Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer Kim ST11, Jang KT2, Lee J1, Jang HM3, Choi HJ4, Jang HL1, Park SH1, Park YS1, Lim HY1, Kang WK1, Park JO5.
    View PubMed
  • Sci Rep. 2014 Dec 23;4:7592. doi: 10.1038/srep07592. Anti-tumor efficacy of fulvestrant in estrogen receptor positive gastric cancer Yi JH11, Do IG2, Jang J3, Kim ST3, Kim KM4, Park SH3, Park JO3, Park YS3, Lim HY3, Kang WK3, Lee J3.
    View PubMed
  • Eur J Cancer. 2014 Nov;50(16):2822-30. doi: 10.1016/j.ejca.2014.08.005. Epub 2014 Sep 15. Simvastatin plus capecitabine-cisplatin versus placebo plus capecitabine-cisplatin in patients with previously untreated advanced gastric cancer: A double-blind randomised phase 3 study Kim ST11, Kang JH2, Lee J1, Park SH1, Park JO1, Park YS1, Lim HY1, Hwang IG3, Lee SC4, Park KW5, Lee HR6, Kang WK7.
    View PubMed
  • BMC Cancer. 2014 Nov 26;14:883. doi: 10.1186/1471-2407-14-883. S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial Kim ST1, Hong YS, Lim HY, Lee J, Kim TW, Kim KP, Kim SY, Baek JY, Kim JH, Lee KW, Chung IJ, Cho SH, Lee KH, Shin SJ, Kang HJ, Shin DB, Lee JW, Jo SJ, Park YS1.
    View PubMed
  • Mol Cancer Ther. 2014 Nov;13(11):2527-36. doi: 10.1158/1535-7163.MCT-14-0255. Epub 2014 Sep 23. Pazopanib, a Novel Multitargeted Kinase Inhibitor, Shows Potent In Vitro Antitumor Activity in Gastric Cancer Cell Lines with FGFR2 Amplification Kim ST11, Jang HL2, Lee SJ1, Lee J1, Choi YL3, Kim KM3, Cho J4, Park SH1, Park YS1, Lim HY1, Yashiro M5, Kang WK1, Park JO6.
    View PubMed
  • PLoS One. 2014 Nov 5;9(11):e111693. doi: 10.1371/journal.pone.0111693. eCollection 2014. High-Throughput Sequencing and Copy Number Variation Detection Using Formalin Fixed Embedded Tissue in Metastatic Gastric Cancer Kim S11, Lee J2, Hong ME3, Do IG3, Kang SY1, Ha SY1, Kim ST2, Park SH2, Kang WK2, Choi MG4, Lee JH4, Sohn TS4, Bae JM4, Kim S4, Kim DH5, Kim KM3.
    View PubMed
  • Cancer?Genomics Proteomics.?2014 Sep-Oct;11(5):259-66. Transcriptome Analysis of CD133-positive Stem Cells and Prognostic Value of Survivin in Colorectal Cancer Kim ST11,?Sohn I2,?DO IG3,?Jang J4,?Kim SH3,?Jung IH5,?Park JO1,?Park YS1,?Talasaz A6,?Lee J1,?Kim HC7.
    View PubMed
  • Cancer Res Treat. 2014 Jan;46(1):48-54. doi: 10.4143/crt.2014.46.1.48. Epub 2014 Jan 15. Dose KRAS Mutation Status Affect on the Effect of VEGF Therapy in Metastatic Colon Cancer Patients Kim ST11, Park KH2, Shin SW2, Kim YH2.
    View PubMed